MADRIGAL PHARMACEUTICALS, INC. Funds and ETFs Madrigal Pharmaceuticals, Inc.
Equities
MDGL
US5588681057
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 194.4 USD | -5.02% |
|
-12.54% | -15.99% |
ETFs positioned on Madrigal Pharmaceuticals, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.35% | 0 M€ | 0.00% | - | |
| 0.08% | 0 M€ | 0.00% | - | |
| 0.04% | 773 M€ | -.--% | - | |
| 0.01% | 9 M€ | +5.51% | - | |
| 0.01% | 147 M€ | +4.88% | - | |
| 0.01% | 9 M€ | -.--% | - | |
| 0.01% | 18 M€ | +3.26% | - | |
| 0.00% | 34 M€ | +2.22% | - |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
194.4
USD
Average target price
377.1
USD
Spread / Average Target
+93.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.99% | 4.08B | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.79% | 22.02B | |
| -17.84% | 20.9B | |
| -11.11% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- MDGL Stock
- Funds and ETFs Madrigal Pharmaceuticals, Inc.
